Lantheus Holdings, Inc
LNTH
Key stats
- Open
- 101.60
- Day high
- 101.80
- Day low
- 101.09
- Previous close
- 101.60
- Volume
- 1.19M
- VWAP
- 101.41
- 52-week high
- 111.86
- 52-week low
- 51.47
- Market cap
- 6.64B
- Shares out
- 65.30M
- Employees
- 1,193
- Listed
- 2015
About Lantheus Holdings, Inc
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · BEDFORD, MA · lantheus.com
Options · expiring Nov 20
Nov 12, 3:59 PM ET- Call open interest
- 238
- Put open interest
- 7
- Put/call
- 0.03
- At-the-money IV
- 20.2%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 90 call | 10.74 | Sep 22, 2:26 PM | 89 | 197 | 0.1% |
| 95 call | 4.50 | Nov 2, 9:30 AM | 38 | 36 | — |
| 100 put | 0.05 | Sep 29, 11:49 AM | 4 | 2 | 16.8% |
| 105 call | 0.05 | Sep 21, 3:44 PM | 3 | 1 | 29.5% |
| 95 put | 0.05 | Oct 6, 12:31 PM | 2 | 5 | 48.9% |
| 85 call | 15.70 | Sep 22, 1:30 PM | 1 | 3 | 0.1% |
Quarterly results
Massive · Nov 5, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $389.91M | $388.18M | $377.33M | $406.79M |
| Gross profit | $243.41M | $241.85M | $230.92M | $240.88M |
| Operating income | $32.21M | $100.22M | $81.33M | $77.18M |
| Net income | $22.37M | $75.03M | $118.42M | $54.09M |
| Diluted EPS | 0.33 | 1.11 | 1.80 | 0.84 |
| Operating cash flow | $101.97M | $92.20M | $125.13M | $90.18M |
| Assets | $2.46B | $2.41B | $2.35B | $2.23B |
| Liabilities | $1.10B | $1.10B | $1.13B | $1.14B |
| Equity | $1.36B | $1.31B | $1.21B | $1.09B |
Technicals
Massive · Nov 12, 2026- 50-day average100.31
- 200-day average92.93
- RSI (14 days)60.4
Short interest
Massive · Oct 30, 2026- Oct 30, 20263.64M shares · 3.2 days to cover
- Oct 15, 20263.63M shares · 4.5 days to cover
- Sep 30, 20263.78M shares · 3.6 days to cover
- Sep 15, 20264.04M shares · 4.1 days to cover
News coverage
No stories about Lantheus Holdings, Inc right now.